Mirtazapine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00370 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 25 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Ohdo syndrome and variants | KG + DL |
| 2 | blepharophimosis - intellectual disability syndrome, Ohdo type | KG + DL |
| 3 | benign paroxysmal torticollis of infancy | KG + DL |
| 4 | ligneous conjunctivitis | KG + DL |
| 5 | childhood apraxia of speech | KG + DL |
| 6 | dysthymic disorder | KG + DL |
| 7 | agoraphobia | KG + DL |
| 8 | phobic disorder | KG + DL |
| 9 | melancholia | KG + DL |
| 10 | neurotic depression | KG + DL |
| 11 | post-traumatic stress disorder | KG + DL |
| 12 | obsessive-compulsive disorder | KG + DL |
| 13 | mixed anxiety and depressive disorder | KG + DL |
| 14 | Keppen-Lubinsky syndrome | KG + DL |
| 15 | chromosome 15q26-qter deletion syndrome | KG + DL |
| 16 | schizoid personality disorder | KG + DL |
| 17 | schizotypal personality disorder | KG + DL |
| 18 | paranoid personality disorder | KG + DL |
| 19 | histrionic personality disorder (disease) | KG + DL |
| 20 | congenital isolated adrenocorticotropic hormone deficiency (disease) | KG + DL |
| 21 | surfactant metabolism dysfunction, pulmonary | KG + DL |
| 22 | autosomal dominant slowed nerve conduction velocity | KG + DL |
| 23 | myofascial pain syndrome | KG + DL |
| 24 | neurotic disorder | KG + DL |
| 25 | familial hypertryptophanemia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.